^
    Back
    Association details:
    Biomarker:BRAF V600K
    Cancer:Solid Tumor
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    onalespib (AT13387) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    Excerpt:
    ...Patients must have histologically confirmed, BRAF-mutant (V600E/K) solid tumor...
    Trial ID:
    NCT02097225
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

    Published date:
    05/13/2020
    Excerpt:
    HSP90 inhibition combined with BRAF/MEK inhibition was determined to be safe with evidence of disease control in a heavily pre-treated population of pts with BRAF V600E/K mut solid tumors.
    DOI:
    10.1200/JCO.2020.38.15_suppl.3609
    Trial ID:
    NCT02097225